Nasus Pharma Completes IPO Raising $10 Million to Advance Drug Development
Nasus Pharma issued a letter to its shareholders from its Chief Executive Officer, Dan Teleman. "Dear Shareholders, 2025 has been a transformational year for Nasus Pharma. We've made considerable progress building a strong, focused company with significant clinical impact, by developing drug delivery products based on our proprietary Nasax powder technology, which has the potential to enhance intranasal drug absorption for improved outcomes... To progress towards fulfilling our mission to innovate the field of life-saving medications, we successfully completed our initial public offering in August 2025, raising $10 million in gross proceeds and strengthening Nasus Pharma's financial position. We have carried this positive momentum forward by advancing NS002's clinical development alongside our goal to ultimately bring a fast-acting, intranasal epinephrine delivery product to market... We have concluded the year by further advancing NS002's development program... We've made significant headway this year in our mission to transform anaphylaxis treatment and deliver epinephrine effectively while offering patients the ease and convenience of a simple nasal spray. We've steered Nasus toward meaningful progress in 2026, driven by the achievement of key planned regulatory and clinical milestones: topline readout from NS002's Phase 2 clinical study planned for the end of the first quarter of 2026, NS002 Investigational New Drug submission planned for the third quarter of 2026, NS002 pivotal study initiation planned for the third quarter of 2026, NS002 pediatric study initiation planned for the fourth quarter in 2026"
Trade with 70% Backtested Accuracy
Analyst Views on NSRX
About NSRX
About the author
Nasus Pharma Secures $15 Million in Private Placement Financing
- Financing Size: Nasus Pharma has entered into a securities purchase agreement for a private placement of $15 million, expected to close on February 12, 2026, with proceeds aimed at advancing the clinical development of NS002 and other pipeline products.
- Share Issuance Details: The private placement will issue 2,695,425 ordinary shares and the same number of warrants, priced at $5.565 per share, with warrants exercisable at $6.53, reflecting investor confidence in the company's growth potential.
- Market Reaction: The placement price exceeds Nasus Pharma's recent closing price, indicating a positive outlook from investors regarding the company's future market performance, which may have a favorable impact on its stock price.
- Strategic Use: The company intends to use the net proceeds to advance pivotal clinical studies for NS002, initiate first-in-human trials for other products, and for general corporate purposes, demonstrating its ongoing commitment to innovative drug development.
Nasus Pharma Prices $15M Private Placement to Fund Clinical Trials
- Private Placement Size: Nasus Pharma successfully priced a $15 million private placement involving 2,695,425 ordinary shares and matching warrants at $5.565 per unit, reflecting market confidence in its future prospects as it exceeds the prior NYSE American close.
- Warrant Terms: The warrants have an exercise price of $6.53, are immediately exercisable, and will expire either two years from issuance or 30 trading days after the NS002 pivotal study results, providing investors with a potential profit opportunity.
- Clear Use of Proceeds: The net proceeds from this financing will fund the advancement of NS002's pivotal trial, first-in-human studies for other intranasal products, and general corporate needs, ensuring ongoing investment in research and operations.
- Investor Participation: Both new and existing investors, including board members, participated in this private placement, demonstrating trust and support for Nasus Pharma's future development, with the placement expected to close on or about February 12, 2026.
Nasus Pharma Enhances Leadership by Appointing Eyal Rubin as Executive Vice President and CFO
New Executive Appointment: Nasus Pharma has appointed Eyal Rubin as Executive Vice President and Chief Financial Officer, bringing over 20 years of financial leadership experience in the biotechnology and pharmaceutical sectors.
Role and Responsibilities: Mr. Rubin will oversee financial operations, including corporate finance, financial planning, capital strategy, and investor relations, as the company progresses its intranasal therapeutics pipeline.
Company's Focus: Nasus Pharma is developing innovative intranasal products, including a needle-free alternative to Epinephrine autoinjectors for anaphylaxis, utilizing proprietary powder-based intranasal technology for rapid drug delivery.
Leadership Confidence: The company's leadership expresses confidence in Mr. Rubin's expertise to enhance financial and operational capabilities, supporting the advancement of clinical programs and long-term growth.
Nasus Pharma Secures $15 Million in Private Placement Financing
- Financing Size: Nasus Pharma has entered into a securities purchase agreement for a private placement of $15 million, expected to close on February 12, 2026, with proceeds aimed at advancing the clinical development of NS002 and other pipeline products.
- Share Issuance Details: The private placement will issue 2,695,425 ordinary shares and the same number of warrants, priced at $5.565 per share, with warrants exercisable at $6.53, reflecting investor confidence in the company's growth potential.
- Market Reaction: The placement price exceeds Nasus Pharma's recent closing price, indicating a positive outlook from investors regarding the company's future market performance, which may have a favorable impact on its stock price.
- Strategic Use: The company intends to use the net proceeds to advance pivotal clinical studies for NS002, initiate first-in-human trials for other products, and for general corporate purposes, demonstrating its ongoing commitment to innovative drug development.
Nasus Pharma Prices $15M Private Placement to Fund Clinical Trials
- Private Placement Size: Nasus Pharma successfully priced a $15 million private placement involving 2,695,425 ordinary shares and matching warrants at $5.565 per unit, reflecting market confidence in its future prospects as it exceeds the prior NYSE American close.
- Warrant Terms: The warrants have an exercise price of $6.53, are immediately exercisable, and will expire either two years from issuance or 30 trading days after the NS002 pivotal study results, providing investors with a potential profit opportunity.
- Clear Use of Proceeds: The net proceeds from this financing will fund the advancement of NS002's pivotal trial, first-in-human studies for other intranasal products, and general corporate needs, ensuring ongoing investment in research and operations.
- Investor Participation: Both new and existing investors, including board members, participated in this private placement, demonstrating trust and support for Nasus Pharma's future development, with the placement expected to close on or about February 12, 2026.
Nasus Pharma Enhances Leadership by Appointing Eyal Rubin as Executive Vice President and CFO
New Executive Appointment: Nasus Pharma has appointed Eyal Rubin as Executive Vice President and Chief Financial Officer, bringing over 20 years of financial leadership experience in the biotechnology and pharmaceutical sectors.
Role and Responsibilities: Mr. Rubin will oversee financial operations, including corporate finance, financial planning, capital strategy, and investor relations, as the company progresses its intranasal therapeutics pipeline.
Company's Focus: Nasus Pharma is developing innovative intranasal products, including a needle-free alternative to Epinephrine autoinjectors for anaphylaxis, utilizing proprietary powder-based intranasal technology for rapid drug delivery.
Leadership Confidence: The company's leadership expresses confidence in Mr. Rubin's expertise to enhance financial and operational capabilities, supporting the advancement of clinical programs and long-term growth.
